• ODYSSEY OUTCOMES: Value of alirocumab increases with higher baseline LDL

    6 days ago - By Healio

    CHICAGO - The PCSK9 inhibitor alirocumab was cost effective up to $6,319 per year at a willingness to pay threshold of $100,000, according to an economic analysis of the ODYSSEY OUTCOMES trial presented at the American Heart Association Scientific Sessions.
    As Cardiology Today previously reported, reducing LDL to very low levels with alirocumab lowered risk for major adverse CV events and all-cause mortality in patients with ACS on statin therapy. The full results from the ODYSSEY OUTCOMES trial were published on Nov. 7 in The New England Journal of Medicine.
    In
    Read more ...